With Zero observations
Natco Pharma announced the successful completion of regulatory inspection from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) facility in Mekaguda Village, near Hyderabad, India, which was conducted during the period 12 February, 2018 to 16 February, 2018. The regulatory audit resulted in zero observations (no form 483 issued).Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
